{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:41:32Z","timestamp":1761100892906},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,11,15]],"date-time":"2006-11-15T00:00:00Z","timestamp":1163548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oral chronic graft versus host disease (cGVHD) is common and a major cause of morbidity and loss of quality of life in long term survivors. Cyclosporine with prednisone remains the first line therapy for oral manifestations of cGVHD. However, even with routine administration of systemic agents, many patients with oral manifestations of cGVHD do not have resolution of their disease and may benefit from incorporation of local therapy. Budesonide is a highly potent steroid which has minimal systemic side effects and being used for oral cGVHD. We designed a retrospective study to compare treatment results of patients with oral cGVHD who received topical budesonide in addition to systemic therapy that consists of combined prednisone and cyclosporine (Group A, <jats:italic>n<\/jats:italic> = 12), with the treatment results of patients who were administered the same systemic therapy alone (Group B, <jats:italic>n<\/jats:italic> = 11) to determine whether budesonide mouthwash had any advantage on response rates. Three mg topical budesonide\/10 ml saline was used 3\u20134 times a day for up to 6 months in group A. Diagnosis, clinical staging, and treatment response scoring for cGVHD were performed according to National Institutes of Health (NIH) consensus criteria. At the baseline examination, there were no statistically significant differences in terms of median oral cGVHD examination scores between two groups. After treatment, there was statistically significant decrease in median oral cGVHD examination scores compared to baseline (<jats:italic>P<\/jats:italic> &lt; 0.001 and 0.021), and significant differences were found between two groups (<jats:italic>P<\/jats:italic> &lt; 0.032). Overall response rate was 83% and 36% for group A and B, respectively (<jats:italic>P<\/jats:italic> = 0.036). However, no statistically significant differences were found between median pain scores of two groups before and after treatment (<jats:italic>P<\/jats:italic> = 0.740 and <jats:italic>P<\/jats:italic> = 0.091). No major systemic side effects and oral candidiasis were observed in two groups of patients. We concluded that topical budesonide might be added to systemic therapy to obtain better response rates in patients with oral cGHVD. Am. J. Hematol., 2007. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20814","type":"journal-article","created":{"date-parts":[[2006,11,17]],"date-time":"2006-11-17T19:42:28Z","timestamp":1163792548000},"page":"349-356","source":"Crossref","is-referenced-by-count":30,"title":["The effect of budesonide mouthwash on oral chronic graft versus host disease"],"prefix":"10.1002","volume":"82","author":[{"given":"Ismail","family":"Sari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130smail","family":"Kocyigit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yildiray","family":"Sisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Eser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aydin","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turgay","family":"Fen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayten","family":"Ferahbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,11,15]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"635","volume-title":"Hematopoietic Cell Transplantation","author":"Sullivan KM","year":"2004"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90380-0"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12234170"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3141"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/10454411970080020701"},{"key":"e_1_2_1_7_2","first-page":"736","article-title":"Pharmacologic prophylaxis of acute graft\u2010versus\u2010host disease after allogeneic marrow transplantation","volume":"12","author":"Schwinghammer TL","year":"1993","journal-title":"Clin Pharm"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.131.8.964"},{"key":"e_1_2_1_9_2","first-page":"227","article-title":"Major salivary gland involvement in graft\u2010vs.\u2010host disease: Considerations related to pathogenesis, the role of cytokines and therapy","volume":"5","author":"Nagler RM","year":"1999","journal-title":"Cytokines Cell Mol Ther"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2.4.243"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703352"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/moe.2001.111130"},{"key":"e_1_2_1_13_2","first-page":"81","article-title":"Topical cyclosporine A for treatment of oral chronic graft\u2010versus\u2010host disease","volume":"13","author":"Epstein JB","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(98)90123-8"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(99)70059-4"},{"key":"e_1_2_1_16_2","first-page":"375","article-title":"Budesonide. An updated review of its pharmacological properties and therapeutic effects in asthma and rhinitis","volume":"44","author":"Brogdan RN","year":"1992","journal-title":"Drugs"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311304"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.01.008"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.267","article-title":"Chronic graft\u2010versus\u2010host disease in 52 patients: Adverse natural course and successful treatment with combination immunosupression","volume":"57","author":"Sullivan K","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0011"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.01.043"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.2.555.555"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.48"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11669216"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.10.004"},{"key":"e_1_2_1_27_2","first-page":"837","article-title":"Response to mycophenolate mofetil therapy in refractory chronic graft\u2010versus\u2010host disease","volume":"88","author":"Busca A","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2002.00448.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70058-9"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1182\/blood.V89.7.2298","article-title":"Treatment of chronic graft\u2010versus\u2010host disease with clofazimine","volume":"89","author":"Lee S","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.9.3604.bloodjournal8693604"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200307000-00020"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705022"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2004.00102.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(96)80198-3"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702192"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2004.02.003"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550050-00006"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70125-3"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8964395"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702055"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1067\/moe.2003.23"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20814","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T17:26:40Z","timestamp":1699982800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,15]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1002\/ajh.20814"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20814","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,15]]}}}